Though there are many elements in the tumor microenvironment that favor a pro or anticancer response, we now understand that the success of many approved cancer therapies ultimately depends on the sustained activation of TAA-specific CD8+ T cells through DCs.9,11,12 For example, the “DC-T cell axis” is required for response to immune checkpoint blockade (ICB) therapy. This evidence concerns the gene CD8A and cancer.